Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:PCYC

Pharmacyclics (PCYC) Stock Price, News & Analysis

Pharmacyclics logo

About Pharmacyclics Stock (NASDAQ:PCYC)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Pharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company's commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. The Company markets IMBRUVICA in the United States for four United States. Food and Drug Administration (FDA) approved indications for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17 (del 17p CLL); mantle cell lymphoma (MCL) who have received at least one prior therapy, and all lines of Waldenstrom's macroglobulinemia (WM). It is also pursuing the development of IMBRUVICA for Graft versus host disease (GvHD). In addition, it has a pre-clinical testing program underway to develop inhibitors of BTK for inflammatory and autoimmune diseases.

Receive PCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharmacyclics and its competitors with MarketBeat's FREE daily newsletter.

PCYC Stock News Headlines

A new coin is elbowing its way to the top of the crypto world
With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only set to be released from its constraints … it could be about to explode. Trump has vowed to roll back Biden’s “crusade against crypto” on his first day in office.
PCYC Historical Data
Pharmacyclics Reaches New 52-Week High (PCYC)
See More Headlines

PCYC Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Pharmacyclics investors own include Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Meta Platforms (META), Baidu (BIDU), Regeneron Pharmaceuticals (REGN), Netflix (NFLX) and Tesla (TSLA).

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:PCYC
CUSIP
71693310
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:PCYC) was last updated on 2/1/2025 by MarketBeat.com Staff
From Our Partners